{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T05:57:02Z","timestamp":1670651822071},"reference-count":38,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma that has traditionally been considered a subgroup of Hodgkin lymphoma. However, morphology, surface marker expression, genetics, and clinical course are different from classic Hodgkin lymphoma. While most patients experience indolent disease with slow progression, some patients can also have more aggressive disease. Nevertheless, outcomes are excellent, and excess mortality due to NLPHL is at most very low. The treatment of newly diagnosed NLPHL has historically mirrored that of classic Hodgkin lymphoma. However, evidence for deviations from that approach has emerged over time and is discussed herein. Less evidence is available for the optimal management of relapsed patients. So-called variant histology has recently emerged as a biological risk factor, providing at least a partial explanation for the observed heterogeneity of NLPHL. Considering variant histology together with other risk factors and careful observation of the clinical course of the disease in each patient can help to assess individual disease aggressiveness. Also important in this mostly indolent disease are the preferences of the patient and host factors, such as individual susceptibility to specific treatment side effects. Considering all this together can guide individualized treatment recommendations, which are paramount in this rare disease.<\/jats:p>","DOI":"10.1182\/hematology.2022000364","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:15:47Z","timestamp":1670602547000},"page":"717-722","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma"],"prefix":"10.1182","volume":"2022","author":[{"given":"Sven","family":"Borchmann","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"26","key":"2022120916114682200_hem2022000364C1","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2019004044","article-title":"How I treat nodular lymphocyte-predominant Hodgkin lymphoma","volume":"136","author":"Eichenauer","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2022120916114682200_hem2022000364C2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pathol.2019.10.003","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell\/histiocyte rich large B-cell lymphoma","volume":"52","author":"Hartmann","year":"2020","journal-title":"Pathology"},{"issue":"3","key":"2022120916114682200_hem2022000364C3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjh.13310","article-title":"Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell\/histiocyte rich large B cell lymphoma","volume":"169","author":"Hartmann","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"2022120916114682200_hem2022000364C4","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"26","key":"2022120916114682200_hem2022000364C5","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2022120916114682200_hem2022000364C6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/ajh.25607","article-title":"The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma","volume":"94","author":"Hartmann","year":"2019","journal-title":"Am J Hematol"},{"key":"2022120916114682200_hem2022000364C7","article-title":"Variant histology in nodular lymphocyte predominant Hodgkin lymphoma in an adult population: disease investigations and characteristics from a retrospective cohort [published online ahead of print 28 April 2022]","author":"Stacey","journal-title":"J Clin Pathol"},{"issue":"1","key":"2022120916114682200_hem2022000364C8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.16290","article-title":"Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016","volume":"189","author":"Posthuma","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2022120916114682200_hem2022000364C9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group","volume":"38","author":"Eichenauer","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"2022120916114682200_hem2022000364C10","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Nogov\u00e1","year":"2005","journal-title":"Ann Oncol"},{"issue":"26","key":"2022120916114682200_hem2022000364C11","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin study group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022120916114682200_hem2022000364C12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"2022120916114682200_hem2022000364C13","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood.2019003877","article-title":"Stage I-II nodular lymphocyte- predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG","volume":"135","author":"Binkley","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2022120916114682200_hem2022000364C14","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018029140","article-title":"Favorable outcomes with de- escalated radiation therapy for limited-stage nodular lymphocyte- predominant Hodgkin lymphoma","volume":"3","author":"Pinnix","year":"2019","journal-title":"Blood Adv"},{"issue":"16","key":"2022120916114682200_hem2022000364C15","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2022120916114682200_hem2022000364C16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41375-019-0609-3","article-title":"Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group","volume":"34","author":"Eichenauer","year":"2020","journal-title":"Leukemia"},{"issue":"20","key":"2022120916114682200_hem2022000364C17","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"34","author":"Appel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"2022120916114682200_hem2022000364C18","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2022120916114682200_hem2022000364C19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.14001","article-title":"Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma","volume":"176","author":"Cencini","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"2022120916114682200_hem2022000364C20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13879","article-title":"Rituximab-ABV(D) for patients with nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy","volume":"175","author":"Garciaz","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2022120916114682200_hem2022000364C21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2022120916114682200_hem2022000364C22","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","article-title":"Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"133","author":"Borchmann","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2022120916114682200_hem2022000364C23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.annonc.2021.02.018","article-title":"PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study","volume":"32","author":"Eichenauer","year":"2021","journal-title":"Ann Oncol"},{"issue":"23","key":"2022120916114682200_hem2022000364C24","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2022120916114682200_hem2022000364C25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/0284186X.2018.1450522","article-title":"R-bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"57","author":"Prusila","year":"2018","journal-title":"Acta Oncol"},{"issue":"6","key":"2022120916114682200_hem2022000364C26","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1111\/bjh.16109","article-title":"Frontline management of nodular lymphocyte predominant Hodgkin lymphoma\u2014a retrospective UK multicentre study","volume":"186","author":"Wilson","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"2022120916114682200_hem2022000364C27","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"2022120916114682200_hem2022000364C28","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2018-02-836437","article-title":"Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","volume":"132","author":"Eichenauer","year":"2018","journal-title":"Blood"},{"key":"2022120916114682200_hem2022000364C29","article-title":"Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group [published online ahead of print 21 March 2022]","author":"Eichenauer","journal-title":"Hematol Oncol"},{"issue":"1","key":"2022120916114682200_hem2022000364C30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2022120916114682200_hem2022000364C31","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/leu.2015.321","article-title":"Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin Study Group","volume":"30","author":"Eichenauer","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2022120916114682200_hem2022000364C32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.24927","article-title":"High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a retrospective study by the European Society for Blood and Marrow Transplantation\u2013Lymphoma Working Party","volume":"93","author":"Akhtar","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"2022120916114682200_hem2022000364C33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2022120916114682200_hem2022000364C34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"2022120916114682200_hem2022000364C35","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"2022120916114682200_hem2022000364C36","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.3390\/cancers13236073","article-title":"Transformed lymphoma is associated with a favorable response to CAR-T-cell treatment in DLBCL patients","volume":"13","author":"Nydegger","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2022120916114682200_hem2022000364C37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/07853890.2022.2046287","article-title":"Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma","volume":"54","author":"Gradel","year":"2022","journal-title":"Ann Med"},{"issue":"6","key":"2022120916114682200_hem2022000364C38","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1002\/ajh.23989","article-title":"Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience: high-grade transformation of NLPHL","volume":"90","author":"Eyre","year":"2015","journal-title":"Am J Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/717\/2021710\/717borchmann.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/717\/2021710\/717borchmann.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:17:15Z","timestamp":1670602635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/717\/493478\/Individualized-patient-care-in-nodular-lymphocyte"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000364","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}